List view / Grid view
The new draft guidance recommends Evrysdi (risdiplam) to treat spinal…
The new draft guidance recommends Evrysdi (risdiplam) to treat spinal muscular atrophy as part of a managed access agreement (MAA).
NICE has published draft guidance recommending cabotegravir, the first long-acting…
NICE has published draft guidance recommending cabotegravir, the first long-acting injectable treatment for HIV-1 infection in adults.
The new draft guidance does not recommend Vimizin (elosulfase alfa)…
The new draft guidance does not recommend Vimizin (elosulfase alfa) for the treatment of Morquio A syndrome following new evidence.
The new draft guidance has recommended dapagliflozin as an option…
The new draft guidance has recommended dapagliflozin as an option for treating certain people with chronic kidney disease (CKD) in adults.
The UK regulator concluded that breast cancer patients taking tucatinib…
The UK regulator concluded that breast cancer patients taking tucatinib live longer, but it is unclear how long for and whether it is cost effective.
Crizanlizumab recommended as a treatment option for preventing recurrent sickle…
Crizanlizumab recommended as a treatment option for preventing recurrent sickle cell crises for people aged 16 and over in the UK.
NICE has recommended Pfizer’s Xeljanz® (tofacitinib) as an option to…
NICE has recommended Pfizer’s Xeljanz® (tofacitinib) as an option to treat polyarticular juvenile arthritis and juvenile psoriatic arthritis.
The UK approval follows a Phase III study in which…
The UK approval follows a Phase III study in which Leqvio® (inclisiran) reduced low-density lipoprotein cholesterol (LDL-C) by 55 percent.
NICE has published draft guidance recommending Eli Lilly's twice-daily pill…
NICE has published draft guidance recommending Eli Lilly's twice-daily pill abemaciclib for advanced HER2-negative breast cancer.
A new approach to the cost-comparison fast-track appraisal process is…
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
NICE has recommended that Ultomiris (ravulizumab) be available on the…
NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
On the NICE’s recommendation, ravulizumab will be made available to…
On the NICE’s recommendation, ravulizumab will be made available to hundreds of patients with paroxysmal nocturnal haemoglobinuria on the UK’s NHS.
The recommendation will allow more data to be collected about…
The recommendation will allow more data to be collected about the combination treatment while allowing patients with high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer to access the medication.
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately…
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately 2,000 NHS patients as a second line treatment for multiple myeloma.
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to…
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
